A naukri.com initiative
Bioengineer
2w
198
Image Credit: Bioengineer
PRL3-zumab: New Anti-Angiogenic Therapy for Eye Diseases
- A team led by Ang, Thura, and Tan introduced PRL3-zumab as a novel anti-angiogenic therapy for neovascular eye disorders.
- Published in Nature Communications, the study explores PRL3-zumab's potential in treating conditions like macular degeneration and diabetic retinopathy.
- PRL3-zumab targets PRL3, a protein involved in abnormal blood vessel growth in ocular tissues, distinct from conventional VEGF inhibitors.
- Research showed PRL3's role in facilitating endothelial cell migration and proliferation and identified it as a viable therapeutic target.
- PRL3-zumab effectively inhibits angiogenesis at a cellular level, reducing vascular leakage and fibrovascular membrane formation.
- The antibody disrupts PRL3's enzymatic activity, impacting key signaling pathways critical for angiogenesis like PI3K/AKT and MAPK.
- PRL3-zumab demonstrated promising safety and efficacy profiles in preclinical models, showing minimal off-target effects and systemic complications.
- Its localized delivery to the eye environment holds potential for effective and targeted treatment with minimal systemic absorption.
- PRL3-zumab's prophylactic potential could shift therapeutic approaches to preventive strategies, preserving vision before irreversible damage occurs.
- The research opens avenues for combination therapies, suggesting synergies with existing anti-VEGF drugs to enhance treatment outcomes.
Read Full Article
11 Likes
For uninterrupted reading, download the app